Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06113809 · ClinicalTrials.gov registry record · Phase 1

Palbociclib and Pembrolizumab in Sarcoma

A Phase 1 study of Sarcoma, sponsored by John Rieth.

Recruiting
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT06113809 is a Phase 1 study of Sarcoma that is actively recruiting participants, run by John Rieth. The registered enrollment target is 8 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06113809, a Phase 1 study of Sarcoma, is actively recruiting participants, sponsored by John Rieth.

RECRUITING
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib in patients with soft tissue sarcomas for which PD-1 inhibitors are approved (includes undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, or alveolar soft part sarcoma).

Conditions Studied

Sarcoma

Interventions

  • DRUG Pembrolizumab
  • DRUG Palbociclib

Study Locations (1)

Iowa

  • University of Iowa Hospitals & Clinics - Iowa City

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-02-01
Est. Completion 2028-07
Phase Phase 1

Sponsor

John Rieth

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06113809

The ClinicalTrials.gov registry entry for NCT06113809 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The listed sponsor is John Rieth, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06113809 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT06113809 about?

NCT06113809 is a clinical study titled "Palbociclib and Pembrolizumab in Sarcoma". This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib in patients with soft tissue sarcomas for which PD-1 inhibitors are approved (includes undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdom...

What is the current status of trial NCT06113809?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-02-01. Estimated completion is 2028-07.

What conditions does trial NCT06113809 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT06113809?

The interventions under investigation include: Pembrolizumab (DRUG), Palbociclib (DRUG).

Who is sponsoring clinical trial NCT06113809?

This trial is sponsored by John Rieth, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06113809 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

Iowa

All trials with a study site in Iowa

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.